Open access
Jul 2026
SYNCRIP drives ferroptosis resistance and metabolic activation via SIRT1 and HK2 in glioblastoma
It is suggested that SYNCRIP is a key regulator of GBM progression by maintaining metabolic homeostasis and ferroptosis resistance, highlighting SYNCRIP as a potential therapeutic target in GBM.
Hyeon Ji Kim, Hyo-Jin Song, Yu Gyung Kim et al.
· International Journal on Bio... · 0 citations